Allergan R&D Innovations recognised with three nominations for the 2014 US Prix Galien Awards
Allergan's R&D pipeline has been recognised by the Galien Foundation, which has nominated three of Allergan's products for the 2014 US Prix Galien Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognises the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.
The Allergan products that have been nominated for the 2014 US Prix Galien Awards are
- Best Biotechnology Product Nominee — Botox (onabotulinumtoxinA) for chronic migraine patients
- Best Pharmaceutical Agent Nominee — Ozurdex (dexamethasone intravitreal implant) 0.7 mg
- Best Medical Technology Nominee — Seri surgical scaffold.
"For more than 64 years, Allergan has remained committed to developing innovative products to address unmet medical needs," said David E.I. Pyott, chairman and CEO, Allergan. "We are proud to be recognised for our R&D efforts by the Prix Galien Committee and especially honored to be the only company to receive nominations in all three of the 2014 Prix Galien Award categories."
Recipients of the Prix Galien Awards will be announced at the Prix Galien US Award Ceremony in New York this fall and are selected by a committee of 10 leaders from the biomedical industry and academia, including five Nobel Laureates.
"Innovation is a key measure of Allergan's commitment to R&D," said Scott M. Whitcup, MD, executive vice president, Research and Development, CSO, Allergan. "With a focus on basic research and clinical development in our specialty areas, we are able to bring novel treatments to market that benefit patients, and are pleased to be recognised by the Galien Foundation for three of these products."